IRP Scientists Recognized for RNA Revelations and Immune System Insights
Since its founding in 1780, the American Academy of Arts & Sciences has honored excellence in fields ranging from the humanities and arts to math, biology, and physics. In 2023, two of IRP’s eminent researchers joined the ranks of such luminaries as Benjamin Franklin and Nobel Prize winner Barbara McClintock as members of the Academy for their work in immunology and RNA science.
Highlighting Drugs and Vaccines Stemming from NIH Discoveries
On May 3, more than six decades of IRP research culminated in the U.S. Food and Drug Administration (FDA) approving the world’s first vaccine for respiratory syncytial virus (RSV), a disease that puts tens of thousands of Americans in the hospital each year and kills thousands. While the new vaccine, called Arexy, has been getting all the headlines recently, it is only the latest example of a slew of FDA-approved medications and vaccines that might never have existed without the tireless efforts of scientists at NIH.
Indeed, a recently published study led by Mark Rohrbaugh, Ph.D., J.D., a special advisor in the NIH Office of Science Policy, found that inventions developed at NIH have contributed to more FDA-approved products than those created at any other nonprofit research institution in the world over the past five decades. NIH tops the study’s list with 27 FDA-approved products, six more than the study attributed to the combined efforts of all the schools in the University of California system.
IRP Research Identifies a Tantalizing Target for Cancer Immunotherapy
February 4 is World Cancer Day, a time to mark international efforts to prevent, detect, and treat cancer. Immunotherapy, one of the most significant advances in treating cancer, was pioneered here at NIH more than 30 years ago. Today, IRP senior investigator Claudia M. Palena, Ph.D., is pushing cancer immunotherapy forward with the discovery of a novel target for cancer vaccines.
New Studies Will Help Efforts to Contain and Treat COVID-19
Most of the time, science is a slow process, with many experiments taking years to yield results. However, as endeavors like the Manhattan Project have shown, scientists can dramatically accelerate the pace of discovery when necessary. Over the past few months, the novel coronavirus pandemic has spurred a burst of research from scientists around the world, including numerous IRP studies. Read on for a round-up of the latest IRP COVID-19 research and learn how IRP investigators are assisting in the fight against the novel coronavirus.
Alexis Shelokov, who studied the polio virus at the NIH in the 1950s and was a powerful scientific force in what would become the famed NIAID Laboratory of Infectious Diseases in Building 7, died on December 16, 2016, in Dallas, Texas. He had a prolific scientific career that took him around the world.
With plans to travel to Swaziland and volunteer with the Baylor International Pediatric AIDS Initiative (BIPAI) and a desire to address issues related to health disparities in the treatment of HIV/AIDS, I began navigating the unfamiliar terrain of life after college.
In his recent State of the Union address, President Barack Obama called America to action and asserted that our researchers can find the cure for cancer, a sentiment that received a standing ovation. We believe that Obama is right.
The NIH is "one of America's great citadels of hope, not only for our people, but also for the world," said President Bill Clinton at the dedication of the Dale and Betty Bumpers Vaccine Research Center (VRC) on June 9, 1999.
Only one building was restricted during the 1951 NIH open house—Building 7, specially designed for infectious disease research. Children under 16 were not admitted. And there was only one demonstration: Dr. Karl Habel of NIH's National Institute of Allergy and Infectious Diseases (NIAID) showed the special procedures necessary in the collecting and handling of material for research on and vaccine development for rickettsial diseases carried by ticks. In this photo, is Dr. Habel following his own advice?
The Ebola vaccine developed by Dr. Nancy Sullivan at NIAID is a Women’s History Month highlight: women developed the vaccine and coordinated and led the clinical trial, and a woman was the first volunteer to receive the vaccine. “That wasn’t planned, but it’s kind of remarkable,” said Sullivan. She explained her work to President Barack Obama in person.
